Astrazeneca Share News (AZN)

AstraZeneca lifts full-year earnings guidance after strong Q3

(Sharecast News) - AstraZeneca lifted its full-year earnings guidance on Thursday following a solid third quarter.

LONDON BRIEFING: AstraZeneca and Haleon lift annual guidance

(Alliance News) - Stocks in London are called lower on Thursday, with a stack of UK corporate updates keeping investors busy until the afternoon's eagerly-anticipated US inflation reading.

Much of biopharma industry yet to set any climate impact targets - report

LONDON, Nov 9 (Reuters) - Much of the global pharmaceutical and biotech industry has yet to set any targets for reducing carbon emissions in line with the Paris Agreement, a new analysis has found, despite the biggest companies in the sector leading the way.

Cancer drugmaker Clovis flags possible bankruptcy

Nov 9 (Reuters) - U.S. drugmaker Clovis Oncology said on Wednesday it was likely to file for bankruptcy "in the very near term", as the company struggles to sell its cancer drug Rubraca.

AstraZeneca celebrates asthma treatment recommendation by US FDA

(Alliance News) - AstraZeneca PLC on Wednesday said it is well-placed to transform current asthma emergency treatment approaches, after its inhaler was recommended by the US Food & Drug Administration.

FDA committee votes in favour of AstraZeneca asthma candidate

(Sharecast News) - AstraZeneca announced on Wednesday that a US Food and Drug Administration (FDA) committee has voted in favour of an adult asthma treatment.

IN BRIEF: Beximco Pharmaceuticals revenue up thanks to domestic sales

Beximco Pharmaceuticals Ltd - Dhaka-based generic pharmaceutical products and active pharmaceutical ingredients maker - In the financial year that ended June 30, books pretax profit of BDT6.69 billion, around GBP57.6 million, up 4.9% from BDT6.37 billion a year before. Annual revenue climbs 18% to BDT34.67 billion from BDT29.49 billion, with domestic sales rising by 21% and export sales by 14%. Declares BDT3.5 per share dividend.

AstraZeneca notes positive phase III analysis for heart failure drug

(Alliance News) - AstraZeneca PLC on Monday shared more positive data for Farxiga for use in the treatment of heart failure.

FTSE 100 lags European peers as GSK, stronger pound weigh

FTSE 100 down 0.5%, FTSE 250 adds 1.2%

*

Miners drive FTSE 100's best week in almost two years

FTSE logs best week since Jan 2021

*

Lilly, Boehringer say Jardiance slows kidney disease progression in trial

FRANKFURT, Nov 4 (Reuters) - Boehringer Ingelheim and Eli Lilly said their diabetes drug Jardiance was shown to slow the progression of chronic kidney disease (CKD), as they seek to catch up with market segment leader AstraZeneca.

LONDON MARKET OPEN: FTSE 100 boosted by miners as commodities rise

(Alliance News) - Stocks were higher in London early Friday, as mining stocks lifted the FTSE 100, buoyed by rumours of an end to China's zero-tolerance Covid policies.

TOP NEWS: AstraZeneca's Beyfortus wins EU approval for RSV in newborns

(Alliance News) - AstraZeneca PLC on Friday said its respiratory syncytial virus treatment Beyfortus, or nirsevimab, which it develops with Sanofi SA, has received EU approval for prevention of the virus in newborns and infants.

LONDON BRIEFING: Stocks called higher; US job growth expected to slow

(Alliance News) - Stock prices in London were called higher on Friday in the wake of US Federal Reserve and Bank of England rate hikes, as markets now await a key US jobs report, expected to show a softening in the labour market.

Astrazeneca's Beyfortus receives EU approval

(Sharecast News) - Drugmaker AstraZeneca said on Friday that its Beyfortus asset had received European Union approval for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants.